-
1 Comment
Shandong Xinhua Pharmaceutical Company Limited is currently in a long term downtrend where the price is trading 8.5% below its 200 day moving average.
From a valuation standpoint, the stock is 90.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.9.
Shandong Xinhua Pharmaceutical Company Limited's total revenue rose by 13.3% to $1B since the same quarter in the previous year.
Its net income has increased by 28.4% to $79M since the same quarter in the previous year.
Finally, its free cash flow fell by 948.0% to $-64M since the same quarter in the previous year.
Based on the above factors, Shandong Xinhua Pharmaceutical Company Limited gets an overall score of 3/5.
| ISIN | CNE000000BG1 |
|---|---|
| Sector | Healthcare |
| Industry | Drug Manufacturers-Specialty & Generic |
| CurrencyCode | CNY |
| Exchange | SHE |
| Target Price | 13.95 |
|---|---|
| Dividend Yield | 0.6% |
| Market Cap | 13B |
| PE Ratio | 39.93 |
| Beta | 0.09 |
Shandong Xinhua Pharmaceutical Company Limited, through its subsidiaries, develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products. It operates through Chemical bulk drugs, Preparations, and Chemical intermediates and Others segments. The company offers active pharmaceutical ingredients, pharmaceutical preparations, and chemical products, such as antipyretic analgesics; drugs for cardiovascular and cerebrovascular diseases; anti-infectives; drugs for diseases related to the central nervous system; and other drugs under the Xinhua brand. It also provides prepared Chinese herbal medicine decoction, traditional Chinese medicines, chemical preparations, antibiotics, biochemical medicines, chemical bulk drugs, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc.; and chemical raw materials, such as dimethyl sulfate, isobutylbenzene, 1,8-diazabicyclo, undec-7-ene, and tetramethylguanidine. In addition, the company offers materials and intermediates, powders for injection and tablets; tablets, hard capsules, granules, and dry suspension; imports and exports goods and technologies; designs medical projects; and health products research and development activities. Further, it engages in the certification business; electrical equipment engineering; and installation and testing of chemical equipment and electrical equipment, as well as the sale of mechanical, hardware, and electrical equipment. Additionally, the company produces and sells high-end steroid system APIs and intermediates; and provides internet data, internet sells, and internet information services for pharmaceuticals and medical devices, etc. It operates in the People's Republic of China, the Americas, Europe, and internationally. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 000756.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
